Analysis of treatment with quetiapin in bipolar patients with obsessional symptom

Quetiapine versus placebo in the treatment of obsession symptoms in bipolar patients wih lithium +benzodiazepin medication,A double blind randomized controlled clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190307042963N1

Enrollment

Registered

2019-04-14

Start date

2019-05-22

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Bipolar disorders. Condition 2: Obsessive compulsive disorder. Mood disorder due to known physiological condition with mixed features Obsessive-compulsive disorder

Interventions

Intervention 1: Intervention group: 20 patient give quetiapin with lithium and benzodiazepin, start with 25 mg twice daily and increase 50 mg weekly until 200 mg daily. Intervention 2: Control group:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with impression of bipolare disorder according to dsm v The patients have score of more than 16 in yale brown score The patients have score of equal or lesser than 17 in Young mania questionnaire The patients have score of equal or lesser than 7 in Hamilton depression questionnaire

Exclusion criteria

Exclusion criteria: The patients in acute phase of depression or mania The patients with cardiac, respiratory, renal or GI disorder Pregnant patients

Design outcomes

Primary

Measure	Time frame
Evaluate severity of obsession in bipolar patients. Timepoint: Before intervention and 4,8 and 8 weeks after intervention. Method of measurement: Yale brown scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBahareh Ghahramanpouri

Shiraz University of Medical Sciences

Bahareh.ghahramanpouri@gmail.com+98 71 3647 9531

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026